Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2022 financial results on Thursday, October 27th, 2022 at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s third quarter 2022 financial results in the pre-market hours.

Conference Call and Webcast Information:

Access to the live call:
Go to the investor relations section of the Company’s website at www.amarincorp.com
Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 367970

Access to replay:
Dial in within the United States: 877-481-4010
International dial in:919-882-2331
Access Code: 46629

A replay of the call will also be available through the Company’s website shortly after the call.

About Amarin   

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   

Investor Inquiries:   

Lisa DeFrancesco

Amarin Corporation plc   

IR@amarincorp.com

Media Inquiries:  

Mark Marmur 

Amarin Corporation plc   

PR@amarincorp.com

Staff

Recent Posts

Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants

SINGAPORE, Dec. 9, 2025 /PRNewswire/ -- Immortal Dragons, the $40 million longevity-focused innovation fund, today…

2 hours ago

Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:…

2 hours ago

Campo Indictment Exposes DEA Rotted From Within – While Medical Cannabis Research and Patients Wait Seven Years

A Federal Indictment That Reads Like a Narco-State ThrillerDEA corruption reaches new levels with the…

5 hours ago

Most Americans With OCD Never Receive Effective Treatment, Landmark Study Finds

Analysis by the International OCD Foundation highlights widespread gaps in diagnosis and care BOSTON, MASSACHUSETTS…

5 hours ago

2026 Regulatory Crossfire: New Outlook Survey Reveals Health IT Rules Reshaping U.S. Care Delivery

Black Book Research national survey maps federal, state, and local mandates impacting hospital, physician, and…

5 hours ago

DiagnosTear Technologies Inc. – Confirmation of No Material Change

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

6 hours ago